Should a patient with a positive interferon‑gamma release assay (IGRA) and a negative purified protein derivative (PPD) skin test, who received Bacillus Calmette‑Guérin (BCG) vaccination as a child, be treated for latent tuberculosis infection?

Treatment Recommendation for Positive IGRA, Negative PPD, with Prior BCG Vaccination

Yes, treat for latent tuberculosis infection (LTBI) based on the positive IGRA result. The negative PPD should be disregarded in this BCG-vaccinated patient, as the IGRA is the preferred and more specific test in this clinical scenario.

Rationale for Treatment Decision

IGRA is Preferred Over TST in BCG-Vaccinated Individuals

In patients with prior BCG vaccination, IGRAs should be used preferentially over tuberculin skin testing because they are not affected by BCG vaccination and provide superior specificity. 1 The European consensus specifically states that "IGRA are likely to complement the tuberculin skin test and are preferred in BCG-immunised individuals" 1, and the ATS/IDSA/CDC guidelines recommend performing an IGRA rather than TST in individuals with a history of BCG vaccination 1.

• BCG vaccination causes false-positive TST reactions through cross-reactivity with mycobacterial antigens, but this effect does not impact IGRA results 1, 2, 3
• Studies demonstrate significant discordance between TST and IGRA in BCG-vaccinated populations, with TST showing much higher positivity rates due to vaccine-induced reactivity 4, 5
• The effect of BCG on TST can persist for decades—up to 55 years after vaccination—contrary to the commonly held belief that it wanes after 10 years 6

The Positive IGRA Indicates True LTBI

A positive IGRA result indicates latent M. tuberculosis infection requiring treatment, regardless of TST status. 1

• IGRAs use antigens (ESAT-6 and CFP-10) that are specific to M. tuberculosis and absent from BCG vaccine strains and most nontuberculous mycobacteria 2, 3
• In your patient's case, the positive IGRA represents true infection with M. tuberculosis, while the negative PPD likely reflects either lack of BCG-induced cross-reactivity or waning of any vaccine-related response 1, 4
• The discordance (positive IGRA, negative TST) actually supports the diagnosis of true LTBI rather than BCG effect, as BCG would be expected to cause TST positivity if it were still influencing immune responses 5

Treatment Approach

Exclude Active TB Before Starting LTBI Treatment

Before initiating LTBI treatment, active tuberculosis must be ruled out through symptom screening and chest radiography. 1

• Ask specifically about cough, hemoptysis, fever, night sweats, weight loss, chest pain, shortness of breath, and fatigue 1
• Obtain a chest X-ray to look for cavitation, airspace opacities, pleural effusions, or other radiographic abnormalities suggestive of active disease 1
• If symptoms or radiographic abnormalities are present, pursue full evaluation for active TB with sputum studies before considering LTBI treatment 1

Recommended LTBI Treatment Regimens

Multiple effective treatment options exist for LTBI, with shorter rifamycin-based regimens offering improved completion rates compared to traditional isoniazid monotherapy. 1

The WHO and ATS/CDC recommend the following regimens 1:

• 3 months of weekly rifapentine plus isoniazid (12 doses by directly observed therapy)
• 4 months of daily rifampin alone
• 3 months of daily isoniazid plus rifampin
• 9 months of daily isoniazid (traditional regimen, maximal efficacy but lower completion rates)
• 6 months of daily isoniazid (acceptable alternative)

Monitoring During Treatment

Clinical monitoring should occur monthly, with baseline and periodic laboratory monitoring for patients at risk of hepatotoxicity. 1

• Monthly visits to assess adherence, review symptoms of adverse effects, and reinforce the importance of completion 1
• Baseline liver function tests are indicated, with routine monitoring for patients over 35 years of age or those with risk factors for hepatic disease 1
• Isoniazid should be withheld if transaminase levels exceed 3 times the upper limit of normal with symptoms, or 5 times the upper limit if asymptomatic 1

Key Clinical Pitfalls to Avoid

Do not dismiss the positive IGRA based on the negative TST in a BCG-vaccinated patient—this represents a common error in interpretation. 1

• The negative TST does not rule out LTBI and should not override the positive IGRA result 1
• Failing to treat documented LTBI (positive IGRA) places the patient at risk for progression to active TB, with associated morbidity and mortality 1
• In BCG-vaccinated populations, relying solely on TST leads to both overdiagnosis (false positives from BCG) and underdiagnosis (false negatives in truly infected individuals) 4, 5

The treatment decision should prioritize preventing progression to active TB disease, which carries significant morbidity and mortality risk, over concerns about treatment toxicity in appropriately monitored patients. 1